MCL-1 is a member of the BCL-2 family of proteins important for blocking apoptosis, or programmed cell death. Many types of cancer cells escape the body’s effort to kill them by overexpressing MCL-1.

Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.”

K. Dane Wittrup, PhD, a pioneer in protein engineering technologies who has helped accelerate development of antibody therapies for cancer, will deliver the next Flexner Discovery Lecture on Thursday, March 22.

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

Vanderbilt investigators have used sophisticated cell biological and structural techniques to “classify” mutations in potassium channels, studies that could lead to personalized treatment of heart rhythm disorders.

Vanderbilt investigators and colleagues around the country have made a major discovery that could lead to better ways to treat type 1 diabetes (T1D).